LIGNAMED
LignaMed's experienced team of scientists and life science professionals are dedicated to developing breakthrough treatments for asthma, organ transplant viability, and fibrosis. LignaMed plans to complete preclinical studies on LGM2605 as a lung transplant device in 2021. LignaMed plans to submit a device package for a lung transplant in 2022. Clinical studies for asthma are scheduled to begin in 2022. There is no effective treatment for Th2-low asthma, which affects 170,000 Americans.
LIGNAMED
Industry:
Health Care Life Science Medical Device Product Research
Founded:
2013-01-01
Address:
Philadelphia, Pennsylvania, United States
Country:
United States
Website Url:
http://www.lignamed.com
Total Employee:
11+
Status:
Active
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics Domain Not Resolving Global Site Tag Sitelinks Search Box
Official Site Inspections
http://www.lignamed.com
- Host name: 104.21.82.37
- IP address: 104.21.82.37
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
